AVIEW LCS vs CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Coreline Soft
VS

AI Verdict

AVIEW LCS is an AI-powered solution for diagnostic imaging analysis, focusing on lung cancer screening, COPD, and coronary artery calcification from CT scans. In contrast, the CARTO™ 3 EP Navigation System Software V8.0 is an AI-powered 3D cardiac mapping and navigation system designed for electrophysiologists to diagnose and treat heart rhythm disorders. While both utilize AI within cardiology, their applications are distinct: AVIEW LCS supports non-invasive diagnostic assessment, whereas CARTO™ 3 EP facilitates interventional electrophysiology procedures.

Choose AVIEW LCS if…

Choose AVIEW LCS if your institution requires a comprehensive, AI-powered solution for integrated lung cancer screening, COPD assessment, and coronary artery calcification scoring from a single low-dose CT scan. This tool is ideal for radiology departments focused on enhancing diagnostic accuracy for pulmonary nodules and efficiently managing patient follow-up with automated comparison capabilities.

View AVIEW LCS →

Choose CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 if…

Choose CARTO™ 3 EP Navigation System Software V8.0 if you are an electrophysiologist seeking an advanced, AI-powered 3D cardiac mapping and navigation system for diagnosing and treating complex heart rhythm disorders. This system is specifically designed to provide highly accurate catheter visualization and rapid, high-resolution anatomical maps to optimize ablation procedures for conditions like AFib and VT.

View CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature AVIEW LCS CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00
Pricing Subscription or one-off payment Unknown
Deployment Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) On-premise (system with specialized hardware)
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW LCS

AVIEW LCS demonstrates superior usability by significantly streamlining high-volume diagnostic workflows, with reported reductions of up to 86.7% in radiologist workload and 60-89% in interpretation time and case throughput. Its integration with existing PACS/RIS and automated report generation facilitate a more efficient and less manual diagnostic process for multiple diseases.

Clinical Value

AVIEW LCS

AVIEW LCS offers broad clinical value by providing highly accurate, multi-disease detection and quantification (lung cancer, COPD, CAC, osteoporosis) from a single low-dose CT scan, outperforming human radiologists in certain nodule identification aspects and significantly reducing false negatives in cancer detection. This comprehensive approach enables earlier diagnosis and improved risk stratification for several prevalent and serious conditions.

Pricing & Value

AVIEW LCS

While both tools require direct contact for pricing, AVIEW LCS provides more concrete, quantifiable metrics on its economic benefits, reporting a 79.5% ROI and a 60-71.2% reduction in radiologist reading time. Its multi-disease screening capability from a single scan also suggests a higher value per scan by optimizing resource utilization in diagnostic workflows.

Enterprise Readiness

AVIEW LCS

AVIEW LCS offers greater flexibility with cloud, hybrid, local, and virtualized deployment options, alongside robust integration with PACS/RIS and third-party platforms. [cite: 8 in Enterprise Readiness search] Its proven track record of processing over 2.5 million cases across 19 countries demonstrates strong scalability and adaptability for diverse enterprise IT environments. [cite: 7 in Enterprise Readiness search]

Innovation

CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00

CARTOu2122 3 EP demonstrates pioneering innovation with its FDA-cleared AI algorithm for automated 3D left atrial anatomy creation using intracardiac ultrasound, a first in its class for interventional cardiology. [cite: 7 in Pricing & Value search, 15 in Pricing & Value search] Its unique current- and magnetic-based technology for distortion-free catheter visualization further highlights its advanced technological leadership in complex electrophysiology procedures. [cite: 2 in Enterprise Readiness search]

Support & Docs

CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00

CARTOu2122 3 EP provides a more specialized and immediate support structure, explicitly offering a 'team of clinical specialists' for 'real-time insights' and a 'comprehensive site visit program' for training. [cite: 19 in Pricing & Value search] This hands-on, dedicated support is crucial for a complex interventional system used in high-stakes procedural environments. [cite: 19 in Pricing & Value search]

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature AVIEW LCS CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00
Name AVIEW LCS CARTOu2122 3 EP Navigation System Software V8.0 (FG-5400-00
Company Coreline Soft Co. Biosense Webster, Inc.
Primary Function AI-powered solution for the detection and analysis of lung nodules, lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. FDA-cleared, AI-powered 3D cardiac mapping and navigation system for electrophysiologists, enhancing diagnosis and treatment of heart rhythm disorders.
Tagline AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment Efficiency at Heart. Excellence at Hand.
Key AI Application Automated lung nodule detection and analysis, Emphysema quantification, Coronary Artery Calcification (CAC) scoring Machine learning for enhanced signal analysis, AI/deep-learning for automated 3D left atrial anatomy creation

Videos

Demos, reviews, and walkthroughs featuring AVIEW LCS and CARTO™ 3 EP Navigation System Software V8.0 (FG-5400-00.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

AVIEW LCS is an AI-powered solution for the detection and analysis of lung nodules, integrated analysis of lung cancer, COPD, and coronary artery calcification from low-dose CT scans, primarily serving Cardiology, Oncology, Pulmonology, and Radiology. In contrast, the CARTOu2122 3 EP Navigation System Software V8.0 is an AI-powered 3D cardiac mapping and navigation system specifically designed for electrophysiologists to enhance the diagnosis and treatment of heart rhythm disorders like AFib and VT within Cardiology.
AVIEW LCS leverages AI for automated lung nodule detection and analysis, Lung-RADS classification, nodule volume quantification, emphysema quantification (LAA index), and coronary artery calcification (CAC) scoring (Agatston, volume, mass) from CT images. The CARTOu2122 3 EP Navigation System Software V8.0 utilizes AI and machine learning for advanced catheter location, rapid high-resolution 3D cardiac map creation, enhanced signal analysis and substrate characterization via the CARTO ELEVATEu2122 Module, and automated 3D left atrial anatomy creation through the CARTOSOUNDu2122 FAM Module.
AVIEW LCS is designed for integration with PACS/RIS and other third-party platforms, and provides automated report generation. The CARTOu2122 3 EP Navigation System Software V8.0 features like 'Connection of Choice' aim for streamlined workflow and automatic catheter recognition, and its enhanced CONFIDENSEu2122 Module is for optimized map creation and data validation within the EP lab.
AI Tool Finder
AI-powered search. Results may not be comprehensive.